

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

Recombinant Anti-Bcl6 antibody [EPR11410-43]

RRID:AB_2924917

Type: Antibody

Proper Citation

Abcam Cat# ab172610, RRID:AB_2924917

Antibody Information

URL: http://antibodyregistry.org/AB_2924917

Proper Citation: Abcam Cat# ab172610, RRID:AB_2924917

Target Antigen: Bcl6

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IHC-P

Antibody Name: Recombinant Anti-Bcl6 antibody [EPR11410-43]

Description: This recombinant monoclonal targets Bcl6

Target Organism: human

Clone ID: EPR11410-43

Antibody ID: AB_2924917

Vendor: Abcam

Catalog Number: ab172610

Record Creation Time: 20231110T031317+0000

Record Last Update: 20260829T211651+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Bcl6 antibody [EPR11410-43].

No alerts have been found for Recombinant Anti-Bcl6 antibody [EPR11410-43].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kirschstein E, et al. (2026) Myofibroblast programming blocks differentiation of TLS-organizing fibroblastic reticular cells in pancreatic cancer. Cancer cell, 44(5), 1080.

Liang X, et al. (2025) Limited activation interdependence and differing patterns of the in vivo effects of IKK1 and IKK2 downstream of NIK. Cell reports, 44(10), 116404.

Abe Y, et al. (2025) Distinct follicular T cell subsets regulate lymphoma progression and outcomes. Cancer cell.

Zhang Y, et al. (2024) CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. Cancer cell, 42(8), 1370.

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN- γ axis. Cell reports, 42(8), 112944.